A Phase 3 interventional study of adalimumab in Hidradenitis Suppurativa, sponsored by AbbVie (prior sponsor, Abbott). Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-01-24.
Sponsored by AbbVie (prior sponsor, Abbott) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies in Hidradenitis Suppurativa by AbbVie — 2 open to participants now, 5 under way, 2 of them phase 3. Hidradenitis Suppurativa · AbbVie.
Among the 18 studies in Hidradenitis Suppurativa by AbbVie, this one is the 3rd largest by enrollment of the 11 interventional ones that give a count, is the only one that started in 2012, is one of 6 in phase 3, and was the 3rd registered.
285 studies on the registry are indexed under Hidradenitis Suppurativa; 88 are open to participants now.
Browse Hidradenitis Suppurativa studies →2 of the 18 studies in Hidradenitis Suppurativa by AbbVie are open now, in 12 countries. Recruiting first, the newest first:
AbbVie · Sites in Argentina, Canada, Colombia and 15 more countries
Ages 12+
AbbVie · Sites in United States
Ages 18–75
By country, each count listing its studies:
Of the 61 Hidradenitis Suppurativa studies recruiting now, 33 (54%) set no upper age limit and 17 (28%) stop at 75 or younger; 13 take children under 18; 12 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
First in 2011; this study’s year is marked. 1 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 508 is above the median of 45 across 200 interventional studies indexed under Hidradenitis Suppurativa.
Median enrollment 243 across the 11 interventional studies, 106 across the 6 observational. Of the 12 that completed or were terminated, 8 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under AbbVie (prior sponsor, Abbott), one of the names counted as AbbVie. Under that name alone:
AbbVie (prior sponsor, Abbott) is the lead sponsor of 223 studies on the registry; none are open to participants now.
3 of the studies in Hidradenitis Suppurativa by AbbVie that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06468228Phase 3AbbVieA Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | 2026-12 |
| NCT06524635AbbVieA Study to Assess Molecular Changes in Adult Participants With Moderate to Severe Hidradenitis Suppurativa or With Moderate to Severe Atopic Dermatitis Receiving Subcutaneous Injections of Lutikizumab | 2027-02 |
| NCT07136467AbbVieA Real World Study to Globally Assess Disease Burden in Adolescent and Adult Participants With Alopecia Areata, Vitiligo, or Hidradenitis Suppurativa | 2027-08 |
Add all 3 to your calendar (.ics) → With an account.
Among the 18 studies in Hidradenitis Suppurativa by AbbVie, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study to evaluate the long term safety, tolerability and efficacy of adalimumab in subjects with moderate to severe hidradenitis suppurativa (HS).
HS is a painful, chronic skin disease characterized by recurrent inflamed nodules and abscesses, which may rupture to form fistulas and subsequent scarring. This study is an open-label extension study available to subjects who participated in a prior adalimumab study who meet all the inclusion and none of the exclusion criteria.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subjects who previously participated in a prior Phase 3 AbbVie hidradenitis suppurativa (HS) study (M11-313 or M11-810) and:
Exclusion Criteria:
Adalimumab 40 mg every week.
Biological: adalimumab
Adalimumab pre-filled syringe, administered by subcutaneous injection
Also known as: Humira
Percentage of Participants in the EW/EW/EW, EW/EOW/EW, and EW/PBO/EW Analysis Populations Achieving Clinical Response Per Hidradenitis Suppurativa Clinical Response (HiSCR) at Each Visit
Clinical response per HiSCR defined as percent reduction from baseline of the prior phase 3 study in the abscess and inflammatory nodule ≥ 50% (AN50) with no increase in the abscess count and no increase in the draining fistula count. Last Observation Carried Forward (LOCF): The last completed evaluation from the previous visit was carried forward to impute missing data at later visits.
Time frame: Weeks 2 (first dose of adalimumab in prior phase 3 study), 4, 8, 12, 16, 20, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, and 216
Percentage of Participants in the PBO/EW/EW Analysis Population Achieving Clinical Response Per HiSCR at Each Visit
Clinical response per HiSCR defined as percent reduction from baseline of the prior phase 3 study in the abscess and inflammatory nodule ≥ 50% (AN50) with no increase in the abscess count and no increase in the draining fistula count. LOCF: The last completed evaluation from the previous visit was carried forward to impute missing data at later visits.
Time frame: Entry of Period B in prior phase 3 study, Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, and 204
Percentage of Participants in the PBO/PBO/EW Analysis Population Achieving Clinical Response Per HiSCR at Each Visit
Clinical response per HiSCR defined as percent reduction from baseline of the prior phase 3 study in the abscess and inflammatory nodule ≥ 50% (AN50) with no increase in the abscess count and no increase in the draining fistula count. LOCF: The last completed evaluation from the previous visit was carried forward to impute missing data at later visits.
Time frame: Entry of M12-555, Weeks 4, 8, 12, 18, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, and 192
Percentage of Participants in the EW/EW/EW Analysis Population Who Achieved Abscess and Inflammatory Nodule (AN) Count of 0, 1, or 2 at Each Visit
The percentage of participants with AN counts lowered to 0, 1, or 2 at each visit. LOCF: The last completed evaluation from the previous visit was carried forward to impute missing data at later visits.
Time frame: Weeks 2 (first dose of adalimumab in prior phase 3 study), 4, 8, 12, 16, 20, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, and 216
Percentage of Participants in the EW/EOW/EW, EW/PBO/EW, and PBO/PBO/EW Analysis Populations Who Achieved AN Count of 0, 1, or 2 at Each Visit
The percentage of participants with AN counts lowered to 0, 1, or 2 at each visit. LOCF: The last completed evaluation from the previous visit was carried forward to impute missing data at later visits.
Time frame: Entry of M12-555, Weeks 4, 8, 12, 18, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, and 192
Percentage of Participants in the PBO/EW/EW Analysis Population Who Achieved AN Count of 0, 1, or 2 at Each Visit
The percentage of participants with AN counts lowered to 0, 1, or 2 at each visit. LOCF: The last completed evaluation from the previous visit was carried forward to impute missing data at later visits.
Time frame: Entry of Period B in prior phase 3 study, Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, and 204
Modified Sartorius Score: Change From Baseline to Each Visit for Participants in the EW/EW/EW Analysis Population
The Sartorius Scale is used to quantify the severity of HS. Points are awarded for 12 body areas (left and right axillae, left and right sub/inframammary areas, intermammary area, left and right buttocks, left and right inguino-crural folds, perianal area, perineal area, and other): points were awarded for nodules (2 points for each); abscesses (4 points); fistulas (4 points); scars (1 point); other findings (1 point); and longest distance between two lesions (2-6 points, 0 if no lesions); and if lesions are separated by normal skin (yes-0 points; no-6 points). The total Sartorius score is the sum of the 12 regional scores. Higher scores indicate greater severity of HS. A negative change indicates decrease in severity. LOCF: The last completed evaluation from the previous visit was carried forward to impute missing data at later visits.
Time frame: Baseline (in prior phase 3 study) to Weeks 2 (first dose of adalimumab in prior phase 3 study), 4, 8, 12, 16, 20, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, and 216
Modified Sartorius Score: Change From Baseline to Each Visit for Participants in the EW/EOW/EW, EW/PBO/EW, and PBO/PBO/EW Analysis Populations
The Sartorius Scale is used to quantify the severity of HS. Points are awarded for 12 body areas (left and right axillae, left and right sub/inframammary areas, intermammary area, left and right buttocks, left and right inguino-crural folds, perianal area, perineal area, and other): points were awarded for nodules (2 points for each); abscesses (4 points); fistulas (4 points); scars (1 point); other findings (1 point); and longest distance between two lesions (2-6 points, 0 if no lesions); and if lesions are separated by normal skin (yes-0 points; no-6 points). The total Sartorius score is the sum of the 12 regional scores. Higher scores indicate greater severity of HS. A negative change indicates decrease in severity. LOCF: The last completed evaluation from the previous visit was carried forward to impute missing data at later visits.
Time frame: Baseline (in prior phase 3 study) to Entry of M12-555 and Weeks 4, 8, 12, 18, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, and 192
Modified Sartorius Score: Change From Baseline to Each Visit for Participants in the PBO/EW/EW Analysis Population
The Sartorius Scale is used to quantify the severity of HS. Points are awarded for 12 body areas (left and right axillae, left and right sub/inframammary areas, intermammary area, left and right buttocks, left and right inguino-crural folds, perianal area, perineal area, and other): points were awarded for nodules (2 points for each); abscesses (4 points); fistulas (4 points); scars (1 point); other findings (1 point); and longest distance between two lesions (2-6 points, 0 if no lesions); and if lesions are separated by normal skin (yes-0 points; no-6 points). The total Sartorius score is the sum of the 12 regional scores. Higher scores indicate greater severity of HS. A negative change indicates decrease in severity. LOCF: The last completed evaluation from the previous visit was carried forward to impute missing data at later visits.
Time frame: Baseline (in prior phase 3 study) to Entry of Period B in prior phase 3 study and Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, and 204
Percentage of Participants in the EW/EW/EW Analysis Population Achieving Skin Pain NRS30 - At Worst at Each Visit Among Participants With Baseline Skin Pain NRS At Worst ≥ 3
The Patient's Global Assessment of Skin Pain Numeric Rating Scale (NRS) was used to assess the worst skin pain and the average skin pain due to HS. Ratings for the 2 items range from 0 (no skin pain) to 10 (skin pain as bad as you can imagine). The assessments were completed on a daily diary by participants before they went to bed and responded to the items based on a recall period of the "last 24 hours." The percentage of participants who achieved at least 30% reduction and at least 1 unit reduction from Baseline in the Patient's Global Assessment of Skin Pain (NRS30) - at worst at each visit among participants with baseline skin pain NRS - at worst ≥ 3 are presented. Weekly averages of daily assessments were analyzed. LOCF: The last completed evaluation from the previous visit was carried forward to impute missing data at later visits.
Time frame: Weeks 2 (first dose of adalimumab in prior phase 3 study), 4, 8, 12, 16, 20, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, and 192
Percentage of Participants in the EW/EOW/EW, EW/PBO/EW, and PBO/PBO/EW Analysis Populations Achieving Skin Pain NRS30 - At Worst at Each Visit Among Participants With Baseline Skin Pain NRS At Worst ≥ 3
The NRS was used to assess the worst skin pain and the average skin pain due to HS. Ratings for the 2 items range from 0 (no skin pain) to 10 (skin pain as bad as you can imagine). The assessments were completed on a daily diary by participants before they went to bed and responded to the items based on a recall period of the "last 24 hours." The percentage of participants who achieved at least 30% reduction and at least 1 unit reduction from Baseline in the NRS (NRS30) - at worst at each visit among participants with baseline skin pain NRS - at worst ≥ 3 are presented. Weekly averages of daily assessments were analyzed. LOCF: The last completed evaluation from the previous visit was carried forward to impute missing data at later visits.
Time frame: Entry of M12-555, and Weeks 4, 8, 12, 18, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, and 192
Percentage of Participants in the PBO/EW/EW Analysis Population Achieving Skin Pain NRS30 - At Worst at Each Visit Among Participants With Baseline Skin Pain NRS At Worst ≥ 3
The NRS was used to assess the worst skin pain and the average skin pain due to HS. Ratings for the 2 items range from 0 (no skin pain) to 10 (skin pain as bad as you can imagine). The assessments were completed on a daily diary by participants before they went to bed and responded to the items based on a recall period of the "last 24 hours." The percentage of participants who achieved at least 30% reduction and at least 1 unit reduction from Baseline in the NRS (NRS30) - at worst at each visit among participants with baseline skin pain NRS - at worst ≥ 3 are presented. Weekly averages of daily assessments were analyzed. LOCF: The last completed evaluation from the previous visit was carried forward to impute missing data at later visits.
Time frame: Entry of Period B in prior phase 3 study, Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, and 204
Percentage of Participants in the EW/EW/EW Analysis Population Achieving Skin Pain NRS30 - On Average at Each Visit Among Participants With Baseline Skin Pain NRS On Average ≥ 3
The NRS was used to assess the worst skin pain and the average skin pain due to HS. Ratings for the 2 items range from 0 (no skin pain) to 10 (skin pain as bad as you can imagine). The assessments were completed on a daily diary by participants before they went to bed and responded to the items based on a recall period of the "last 24 hours." The percentage of participants who achieved at least 30% reduction and at least 1 unit reduction from Baseline in the NRS (NRS30) - on average at each visit among participants with baseline skin pain NRS - on average ≥ 3 are presented. Weekly averages of daily assessments were analyzed. LOCF: The last completed evaluation from the previous visit was carried forward to impute missing data at later visits.
Time frame: Weeks 2 (first dose of adalimumab in prior phase 3 study), 4, 8, 12, 16, 20, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, and 192
Percentage of Participants in the EW/EOW/EW, EW/PBO/EW, and PBO/PBO/EW Analysis Populations Achieving Skin Pain NRS30 - On Average at Each Visit Among Participants With Baseline Skin Pain NRS On Average ≥ 3
The NRS was used to assess the worst skin pain and the average skin pain due to HS. Ratings for the 2 items range from 0 (no skin pain) to 10 (skin pain as bad as you can imagine). The assessments were completed on a daily diary by participants before they went to bed and responded to the items based on a recall period of the "last 24 hours." The percentage of participants who achieved at least 30% reduction and at least 1 unit reduction from Baseline in the NRS (NRS30) - on average at each visit among participants with baseline skin pain NRS - on average ≥ 3 are presented. Weekly averages of daily assessments were analyzed. LOCF: The last completed evaluation from the previous visit was carried forward to impute missing data at later visits.
Time frame: Entry of M12-555, and Weeks 4, 8, 12, 18, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, and 192
Percentage of Participants in the PBO/EW/EW Analysis Population Achieving Skin Pain NRS30 - On Average at Each Visit Among Participants With Baseline Skin Pain NRS On Average ≥ 3
The NRS was used to assess the worst skin pain and the average skin pain due to HS. Ratings for the 2 items range from 0 (no skin pain) to 10 (skin pain as bad as you can imagine). The assessments were completed on a daily diary by participants before they went to bed and responded to the items based on a recall period of the "last 24 hours." The percentage of participants who achieved at least 30% reduction and at least 1 unit reduction from Baseline in the NRS (NRS30) - on average at each visit among participants with baseline skin pain NRS - on average ≥ 3 are presented. Weekly averages of daily assessments were analyzed. LOCF: The last completed evaluation from the previous visit was carried forward to impute missing data at later visits.
Time frame: Entry of Period B in prior phase 3 study, Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, and 204
| Milestone | Adalimumab Every Week |
|---|---|
| Started | 508 |
| Completed | 235 |
| Not completed | 273 |
| Withdrew: Adverse event | 46 |
| Withdrew: Lack of efficacy | 76 |
| Withdrew: Exceed protocol-specified interventions | 2 |
| Withdrew: Protocol deviation | 1 |
| Withdrew: Withdrew consent | 67 |
| Withdrew: Lost to follow-up | 53 |
| Withdrew: Other | 28 |
Clinical response per HiSCR defined as percent reduction from baseline of the prior phase 3 study in the abscess and inflammatory nodule ≥ 50% (AN50) with no increase in the abscess count and no increase in the draining fistula count. Last Observation Carried Forward (LOCF): The last completed evaluation from the previous visit was carried forward to impute missing data at later visits.
| percentage of participants | EW/EW/EW | EW/EOW/EW | EW/PBO/EW |
|---|---|---|---|
| Week 2 | 34.1 | 39.8 | 34.1 |
| Week 4 | 38.6 | 41.1 | 40.2 |
| Week 8 | 51.1 | 48.9 | 47.8 |
| Week 12 | 52.3 | 55.6 | 51.1 |
| Week 16 | 50.0 | 56.7 | 45.7 |
| Week 20 | 56.8 | 45.6 | 45.7 |
| Week 24 | 48.9 | 47.8 | 42.4 |
| Week 36 | 62.5 | 54.4 | 52.2 |
| Week 48 | 58.0 | 55.6 | 58.7 |
| Week 60 | 62.5 | 57.8 | 58.7 |
| Week 72 | 59.1 | 61.1 | 53.3 |
| Week 84 | 56.8 | 56.7 | 55.4 |
| Week 96 | 56.8 | 54.4 | 53.3 |
| Week 108 | 60.2 | 56.7 | 53.3 |
| Week 120 | 56.8 | 52.2 | 45.7 |
| Week 132 | 52.3 | 52.2 | 50.0 |
| Week 144 | 51.1 | 54.4 | 52.2 |
| Week 156 | 48.9 | 52.2 | 50.0 |
| Week 168 | 52.3 | 53.3 | 46.7 |
| Week 180 | 51.1 | 54.4 | 46.7 |
| Week 192 | 51.1 | 55.6 | 46.7 |
| Week 204 | 50.0 | 54.4 | 46.7 |
| Week 216 | 50.0 | 54.4 | 46.7 |
Clinical response per HiSCR defined as percent reduction from baseline of the prior phase 3 study in the abscess and inflammatory nodule ≥ 50% (AN50) with no increase in the abscess count and no increase in the draining fistula count. LOCF: The last completed evaluation from the previous visit was carried forward to impute missing data at later visits.
| percentage of participants | PBO/EW/EW |
|---|---|
| Entry of Period B | 26.1 |
| Week 12 | 54.4 |
| Week 24 | 57.9 |
| Week 36 | 57.0 |
| Week 48 | 60.5 |
| Week 60 | 57.0 |
| Week 72 | 50.0 |
| Week 84 | 50.0 |
| Week 96 | 53.5 |
| Week 108 | 52.6 |
| Week 120 | 53.5 |
| Week 132 | 56.1 |
| Week 144 | 51.8 |
| Week 156 | 52.6 |
| Week 168 | 55.3 |
| Week 180 | 54.4 |
| Week 192 | 53.5 |
| Week 204 | 53.5 |
Clinical response per HiSCR defined as percent reduction from baseline of the prior phase 3 study in the abscess and inflammatory nodule ≥ 50% (AN50) with no increase in the abscess count and no increase in the draining fistula count. LOCF: The last completed evaluation from the previous visit was carried forward to impute missing data at later visits.
| percentage of participants | PBO/PBO/EW |
|---|---|
| Entry of M12-555 | 19.5 |
| Week 4 | 46.7 |
| Week 8 | 51.6 |
| Week 12 | 48.4 |
| Week 18 | 57.4 |
| Week 24 | 55.7 |
| Week 36 | 60.7 |
| Week 48 | 54.9 |
| Week 60 | 55.7 |
| Week 72 | 54.9 |
| Week 84 | 54.9 |
| Week 96 | 57.4 |
| Week 108 | 54.9 |
| Week 120 | 52.5 |
| Week 132 | 54.1 |
| Week 144 | 51.6 |
| Week 156 | 50.8 |
| Week 168 | 51.6 |
| Week 180 | 51.6 |
| Week 192 | 51.6 |
The percentage of participants with AN counts lowered to 0, 1, or 2 at each visit. LOCF: The last completed evaluation from the previous visit was carried forward to impute missing data at later visits.
| percentage of participants | EW/EW/EW |
|---|---|
| Week 2 | 22.7 |
| Week 4 | 28.4 |
| Week 8 | 38.6 |
| Week 12 | 35.2 |
| Week 16 | 37.5 |
| Week 20 | 42.0 |
| Week 24 | 36.4 |
| Week 36 | 48.9 |
| Week 48 | 46.6 |
| Week 60 | 43.2 |
| Week 72 | 50.0 |
| Week 84 | 45.5 |
| Week 96 | 44.3 |
| Week 108 | 46.6 |
| Week 120 | 44.3 |
| Week 132 | 44.3 |
| Week 144 | 43.2 |
| Week 156 | 45.5 |
| Week 168 | 46.6 |
| Week 180 | 46.6 |
| Week 192 | 47.7 |
| Week 204 | 47.7 |
| Week 216 | 46.6 |
The percentage of participants with AN counts lowered to 0, 1, or 2 at each visit. LOCF: The last completed evaluation from the previous visit was carried forward to impute missing data at later visits.
| percentage of participants | EW/EOW/EW | EW/PBO/EW | PBO/PBO/EW |
|---|---|---|---|
| Entry of M12-555 | 31.1 | 22.8 | 21.1 |
| Week 4 | 35.6 | 34.8 | 44.3 |
| Week 8 | 43.2 | 42.4 | 53.3 |
| Week 12 | 45.5 | 44.6 | 45.1 |
| Week 18 | 50.0 | 41.3 | 50.0 |
| Week 24 | 43.2 | 46.7 | 57.4 |
| Week 36 | 54.5 | 45.7 | 57.4 |
| Week 48 | 50.0 | 42.4 | 52.5 |
| Week 60 | 48.9 | 43.5 | 51.6 |
| Week 72 | 50.0 | 43.5 | 54.1 |
| Week 84 | 53.4 | 44.6 | 50.8 |
| Week 96 | 51.1 | 40.2 | 52.5 |
| Week 108 | 51.1 | 40.2 | 51.6 |
| Week 120 | 46.6 | 37.0 | 52.5 |
| Week 132 | 51.1 | 37.0 | 53.3 |
| Week 144 | 48.9 | 41.3 | 52.5 |
| Week 156 | 47.7 | 39.1 | 51.6 |
| Week 168 | 51.1 | 35.9 | 51.6 |
| Week 180 | 51.1 | 35.9 | 51.6 |
| Week 192 | 51.1 | 35.9 | 51.6 |
The percentage of participants with AN counts lowered to 0, 1, or 2 at each visit. LOCF: The last completed evaluation from the previous visit was carried forward to impute missing data at later visits.
| percentage of participants | PBO/EW/EW |
|---|---|
| Entry of Period B | 20.0 |
| Week 12 | 38.6 |
| Week 24 | 43.0 |
| Week 36 | 42.1 |
| Week 48 | 43.9 |
| Week 60 | 45.6 |
| Week 72 | 43.9 |
| Week 84 | 43.9 |
| Week 96 | 46.5 |
| Week 108 | 42.1 |
| Week 120 | 45.6 |
| Week 132 | 46.5 |
| Week 144 | 49.1 |
| Week 156 | 45.6 |
| Week 168 | 46.5 |
| Week 180 | 45.6 |
| Week 192 | 45.6 |
| Week 204 | 45.6 |
The Sartorius Scale is used to quantify the severity of HS. Points are awarded for 12 body areas (left and right axillae, left and right sub/inframammary areas, intermammary area, left and right buttocks, left and right inguino-crural folds, perianal area, perineal area, and other): points were awarded for nodules (2 points for each); abscesses (4 points); fistulas (4 points); scars (1 point); other findings (1 point); and longest distance between two lesions (2-6 points, 0 if no lesions); and if lesions are separated by normal skin (yes-0 points; no-6 points). The total Sartorius score is the sum of the 12 regional scores. Higher scores indicate greater severity of HS. A negative change indicates decrease in severity. LOCF: The last completed evaluation from the previous visit was carried forward to impute missing data at later visits.
| units on a scale | EW/EW/EW |
|---|---|
| Week 2 | -18.0 ± 25.27 |
| Week 4 | -21.0 ± 31.81 |
| Week 8 | -22.8 ± 35.45 |
| Week 12 | -23.9 ± 48.30 |
| Week 16 | -26.6 ± 54.63 |
| Week 20 | -32.1 ± 73.69 |
| Week 24 | -36.6 ± 74.99 |
| Week 36 | -41.6 ± 93.11 |
| Week 48 | -42.2 ± 115.22 |
| Week 60 | -41.9 ± 119.98 |
| Week 72 | -43.2 ± 122.30 |
| Week 84 | -42.8 ± 123.18 |
| Week 96 | -43.2 ± 126.21 |
| Week 108 | -43.2 ± 124.92 |
| Week 120 | -43.4 ± 127.65 |
| Week 132 | -42.5 ± 128.45 |
| Week 144 | -42.4 ± 129.37 |
| Week 156 | -40.7 ± 130.30 |
| Week 168 | -41.5 ± 130.40 |
| Week 180 | -41.8 ± 129.89 |
| Week 192 | -41.9 ± 130.46 |
| Week 204 | -41.4 ± 130.72 |
| Week 216 | -41.4 ± 130.94 |
The Sartorius Scale is used to quantify the severity of HS. Points are awarded for 12 body areas (left and right axillae, left and right sub/inframammary areas, intermammary area, left and right buttocks, left and right inguino-crural folds, perianal area, perineal area, and other): points were awarded for nodules (2 points for each); abscesses (4 points); fistulas (4 points); scars (1 point); other findings (1 point); and longest distance between two lesions (2-6 points, 0 if no lesions); and if lesions are separated by normal skin (yes-0 points; no-6 points). The total Sartorius score is the sum of the 12 regional scores. Higher scores indicate greater severity of HS. A negative change indicates decrease in severity. LOCF: The last completed evaluation from the previous visit was carried forward to impute missing data at later visits.
| units on a scale | EW/EOW/EW | EW/PBO/EW | PBO/PBO/EW |
|---|---|---|---|
| Entry of M12-555 | -23.1 ± 56.94 | -10.5 ± 56.74 | 0.2 ± 51.35 |
| Week 4 | -30.2 ± 48.99 | -18.8 ± 56.52 | -16.2 ± 56.16 |
| Week 8 | -34.9 ± 47.42 | -21.2 ± 63.26 | -24.8 ± 51.55 |
| Week 12 | -34.8 ± 55.71 | -25.5 ± 57.92 | -26.2 ± 54.58 |
| Week 18 | -35.9 ± 47.92 | -26.2 ± 60.59 | -32.3 ± 48.60 |
| Week 24 | -37.1 ± 47.39 | -24.1 ± 61.52 | -33.5 ± 50.20 |
| Week 36 | -37.1 ± 46.07 | -24.7 ± 63.81 | -33.6 ± 57.58 |
| Week 48 | -37.5 ± 47.94 | -24.8 ± 63.21 | -30.2 ± 64.84 |
| Week 60 | -34.8 ± 50.17 | -22.6 ± 65.06 | -31.7 ± 66.33 |
| Week 72 | -35.4 ± 55.22 | -20.1 ± 64.52 | -31.8 ± 65.26 |
| Week 84 | -36.6 ± 51.33 | -20.0 ± 66.02 | -29.5 ± 65.79 |
| Week 96 | -34.0 ± 49.42 | -18.3 ± 65.14 | -29.0 ± 68.85 |
| Week 108 | -34.0 ± 54.41 | -18.3 ± 66.88 | -28.4 ± 71.52 |
| Week 120 | -31.8 ± 60.85 | -16.2 ± 66.82 | -28.3 ± 70.37 |
| Week 132 | -35.1 ± 53.01 | -16.7 ± 66.87 | -28.8 ± 69.79 |
| Week 144 | -35.1 ± 53.94 | -16.6 ± 67.30 | -28.6 ± 70.03 |
| Week 156 | -34.7 ± 53.95 | -15.7 ± 67.09 | -28.0 ± 69.11 |
| Week 168 | -35.6 ± 53.72 | -15.5 ± 67.40 | -28.7 ± 69.81 |
| Week 180 | -35.6 ± 53.64 | -15.4 ± 67.39 | -28.7 ± 69.81 |
| Week 192 | -35.6 ± 53.64 | -15.4 ± 67.39 | -28.7 ± 69.81 |
The Sartorius Scale is used to quantify the severity of HS. Points are awarded for 12 body areas (left and right axillae, left and right sub/inframammary areas, intermammary area, left and right buttocks, left and right inguino-crural folds, perianal area, perineal area, and other): points were awarded for nodules (2 points for each); abscesses (4 points); fistulas (4 points); scars (1 point); other findings (1 point); and longest distance between two lesions (2-6 points, 0 if no lesions); and if lesions are separated by normal skin (yes-0 points; no-6 points). The total Sartorius score is the sum of the 12 regional scores. Higher scores indicate greater severity of HS. A negative change indicates decrease in severity. LOCF: The last completed evaluation from the previous visit was carried forward to impute missing data at later visits.
| units on a scale | PBO/EW/EW |
|---|---|
| Entry of Period B | -18.0 ± 38.32 |
| Week 12 | -43.2 ± 48.07 |
| Week 24 | -43.0 ± 53.08 |
| Week 36 | -49.5 ± 57.05 |
| Week 48 | -47.1 ± 61.95 |
| Week 60 | -46.2 ± 60.94 |
| Week 72 | -44.5 ± 67.13 |
| Week 84 | -46.8 ± 64.57 |
| Week 96 | -45.5 ± 70.63 |
| Week 108 | -45.0 ± 74.15 |
| Week 120 | -45.9 ± 75.30 |
| Week 132 | -44.4 ± 78.09 |
| Week 144 | -45.4 ± 76.53 |
| Week 156 | -46.0 ± 76.17 |
| Week 168 | -46.1 ± 75.84 |
| Week 180 | -45.8 ± 75.96 |
| Week 192 | -45.8 ± 75.89 |
| Week 204 | -45.9 ± 75.96 |
The Patient's Global Assessment of Skin Pain Numeric Rating Scale (NRS) was used to assess the worst skin pain and the average skin pain due to HS. Ratings for the 2 items range from 0 (no skin pain) to 10 (skin pain as bad as you can imagine). The assessments were completed on a daily diary by participants before they went to bed and responded to the items based on a recall period of the "last 24 hours." The percentage of participants who achieved at least 30% reduction and at least 1 unit reduction from Baseline in the Patient's Global Assessment of Skin Pain (NRS30) - at worst at each visit among participants with baseline skin pain NRS - at worst ≥ 3 are presented. Weekly averages of daily assessments were analyzed. LOCF: The last completed evaluation from the previous visit was carried forward to impute missing data at later visits.
| percentage of participants | EW/EW/EW |
|---|---|
| Week 2 | 47.6 |
| Week 4 | 46.0 |
| Week 8 | 44.4 |
| Week 12 | 42.9 |
| Week 16 | 46.0 |
| Week 20 | 50.8 |
| Week 24 | 54.0 |
| Week 36 | 58.7 |
| Week 48 | 54.0 |
| Week 60 | 52.4 |
| Week 72 | 54.0 |
| Week 84 | 52.4 |
| Week 96 | 49.2 |
| Week 108 | 54.0 |
| Week 120 | 50.8 |
| Week 132 | 46.0 |
| Week 144 | 54.0 |
| Week 156 | 52.4 |
| Week 168 | 52.4 |
| Week 180 | 52.4 |
| Week 192 | 52.4 |
The NRS was used to assess the worst skin pain and the average skin pain due to HS. Ratings for the 2 items range from 0 (no skin pain) to 10 (skin pain as bad as you can imagine). The assessments were completed on a daily diary by participants before they went to bed and responded to the items based on a recall period of the "last 24 hours." The percentage of participants who achieved at least 30% reduction and at least 1 unit reduction from Baseline in the NRS (NRS30) - at worst at each visit among participants with baseline skin pain NRS - at worst ≥ 3 are presented. Weekly averages of daily assessments were analyzed. LOCF: The last completed evaluation from the previous visit was carried forward to impute missing data at later visits.
| percentage of participants | EW/EOW/EW | EW/PBO/EW | PBO/PBO/EW |
|---|---|---|---|
| Entry of M12-555 | 40.0 | 21.9 | 22.6 |
| Week 4 | 47.5 | 43.1 | 44.6 |
| Week 8 | 45.2 | 47.6 | 51.8 |
| Week 12 | 41.3 | 54.0 | 51.8 |
| Week 18 | 47.6 | 50.8 | 55.4 |
| Week 24 | 42.9 | 47.6 | 54.2 |
| Week 36 | 49.2 | 47.6 | 55.4 |
| Week 48 | 47.6 | 50.8 | 56.6 |
| Week 60 | 47.6 | 50.8 | 50.6 |
| Week 72 | 47.6 | 42.9 | 50.6 |
| Week 84 | 50.8 | 46.0 | 48.2 |
| Week 96 | 50.8 | 55.6 | 48.2 |
| Week 108 | 50.8 | 42.9 | 50.6 |
| Week 120 | 42.9 | 47.6 | 45.8 |
| Week 132 | 41.3 | 47.6 | 48.2 |
| Week 144 | 41.3 | 50.8 | 47.0 |
| Week 156 | 39.7 | 46.0 | 49.4 |
| Week 168 | 41.3 | 49.2 | 48.2 |
| Week 180 | 41.3 | 49.2 | 48.2 |
| Week 192 | 41.3 | 49.2 | 48.2 |
The NRS was used to assess the worst skin pain and the average skin pain due to HS. Ratings for the 2 items range from 0 (no skin pain) to 10 (skin pain as bad as you can imagine). The assessments were completed on a daily diary by participants before they went to bed and responded to the items based on a recall period of the "last 24 hours." The percentage of participants who achieved at least 30% reduction and at least 1 unit reduction from Baseline in the NRS (NRS30) - at worst at each visit among participants with baseline skin pain NRS - at worst ≥ 3 are presented. Weekly averages of daily assessments were analyzed. LOCF: The last completed evaluation from the previous visit was carried forward to impute missing data at later visits.
| percentage of participants | PBO/EW/EW |
|---|---|
| Entry of Period B | 31.6 |
| Week 12 | 51.6 |
| Week 24 | 55.3 |
| Week 36 | 55.8 |
| Week 48 | 53.2 |
| Week 60 | 58.4 |
| Week 72 | 64.9 |
| Week 84 | 63.6 |
| Week 96 | 62.3 |
| Week 108 | 55.1 |
| Week 120 | 56.4 |
| Week 132 | 53.8 |
| Week 144 | 55.1 |
| Week 156 | 51.3 |
| Week 168 | 57.7 |
| Week 180 | 57.7 |
| Week 192 | 56.4 |
| Week 204 | 57.7 |
The NRS was used to assess the worst skin pain and the average skin pain due to HS. Ratings for the 2 items range from 0 (no skin pain) to 10 (skin pain as bad as you can imagine). The assessments were completed on a daily diary by participants before they went to bed and responded to the items based on a recall period of the "last 24 hours." The percentage of participants who achieved at least 30% reduction and at least 1 unit reduction from Baseline in the NRS (NRS30) - on average at each visit among participants with baseline skin pain NRS - on average ≥ 3 are presented. Weekly averages of daily assessments were analyzed. LOCF: The last completed evaluation from the previous visit was carried forward to impute missing data at later visits.
| percentage of participants | EW/EW/EW |
|---|---|
| Week 2 | 56.0 |
| Week 4 | 52.0 |
| Week 8 | 48.0 |
| Week 12 | 46.0 |
| Week 16 | 40.0 |
| Week 20 | 50.0 |
| Week 24 | 46.0 |
| Week 36 | 58.0 |
| Week 48 | 56.0 |
| Week 60 | 56.0 |
| Week 72 | 56.0 |
| Week 84 | 56.0 |
| Week 96 | 54.0 |
| Week 108 | 50.0 |
| Week 120 | 48.0 |
| Week 132 | 56.0 |
| Week 144 | 56.0 |
| Week 156 | 58.0 |
| Week 168 | 56.0 |
| Week 180 | 56.0 |
| Week 192 | 56.0 |
The NRS was used to assess the worst skin pain and the average skin pain due to HS. Ratings for the 2 items range from 0 (no skin pain) to 10 (skin pain as bad as you can imagine). The assessments were completed on a daily diary by participants before they went to bed and responded to the items based on a recall period of the "last 24 hours." The percentage of participants who achieved at least 30% reduction and at least 1 unit reduction from Baseline in the NRS (NRS30) - on average at each visit among participants with baseline skin pain NRS - on average ≥ 3 are presented. Weekly averages of daily assessments were analyzed. LOCF: The last completed evaluation from the previous visit was carried forward to impute missing data at later visits.
| percentage of participants | EW/EOW/EW | EW/PBO/EW | PBO/PBO/EW |
|---|---|---|---|
| Entry of M12-555 | 43.6 | 37.7 | 31.9 |
| Week 4 | 49.0 | 46.8 | 61.8 |
| Week 8 | 46.2 | 55.8 | 61.8 |
| Week 12 | 39.6 | 59.6 | 58.8 |
| Week 18 | 45.3 | 59.6 | 63.2 |
| Week 24 | 39.6 | 53.8 | 54.4 |
| Week 36 | 45.3 | 48.1 | 58.8 |
| Week 48 | 47.2 | 51.9 | 58.8 |
| Week 60 | 43.4 | 53.8 | 55.9 |
| Week 72 | 47.2 | 59.6 | 55.9 |
| Week 84 | 49.1 | 48.1 | 52.9 |
| Week 96 | 47.2 | 57.7 | 57.4 |
| Week 108 | 49.1 | 44.2 | 54.4 |
| Week 120 | 39.6 | 48.1 | 54.4 |
| Week 132 | 43.4 | 50.0 | 54.4 |
| Week 144 | 43.4 | 50.0 | 54.4 |
| Week 156 | 43.4 | 46.2 | 55.9 |
| Week 168 | 43.4 | 48.1 | 54.4 |
| Week 180 | 43.4 | 48.1 | 54.4 |
| Week 192 | 43.4 | 48.1 | 54.4 |
The NRS was used to assess the worst skin pain and the average skin pain due to HS. Ratings for the 2 items range from 0 (no skin pain) to 10 (skin pain as bad as you can imagine). The assessments were completed on a daily diary by participants before they went to bed and responded to the items based on a recall period of the "last 24 hours." The percentage of participants who achieved at least 30% reduction and at least 1 unit reduction from Baseline in the NRS (NRS30) - on average at each visit among participants with baseline skin pain NRS - on average ≥ 3 are presented. Weekly averages of daily assessments were analyzed. LOCF: The last completed evaluation from the previous visit was carried forward to impute missing data at later visits.
| percentage of participants | PBO/EW/EW |
|---|---|
| Entry of Period B | 30.6 |
| Week 12 | 59.2 |
| Week 24 | 61.0 |
| Week 36 | 61.7 |
| Week 48 | 53.3 |
| Week 60 | 60.0 |
| Week 72 | 58.3 |
| Week 84 | 60.0 |
| Week 96 | 61.7 |
| Week 108 | 62.3 |
| Week 120 | 62.3 |
| Week 132 | 59.0 |
| Week 144 | 60.7 |
| Week 156 | 55.7 |
| Week 168 | 62.3 |
| Week 180 | 62.3 |
| Week 192 | 60.7 |
| Week 204 | 62.3 |
Collected over Treatment-emergent adverse events (TEAEs) and serious adverse events (TESAEs) were collected from first dose of study drug until 70 days after the last dose of study drug (up to 225 weeks).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| All Adalimumab | — | 99/508 (19.5%) | 349/508 (68.7%) |
| Event | All Adalimumab |
|---|---|
| HIDRADENITISSkin and subcutaneous tissue disorders | 29/508 |
| PNEUMONIAInfections and infestations | 3/508 |
| OBESITYMetabolism and nutrition disorders | 3/508 |
| ANGINA PECTORISCardiac disorders | 2/508 |
| PALPITATIONSCardiac disorders | 2/508 |
| CHOLELITHIASISHepatobiliary disorders | 2/508 |
| APPENDICITISInfections and infestations | 2/508 |
| CELLULITISInfections and infestations | 2/508 |
| PILONIDAL CYSTInfections and infestations | 2/508 |
| POSTOPERATIVE WOUND INFECTIONInfections and infestations | 2/508 |
| Event | All Adalimumab |
|---|---|
| HIDRADENITISSkin and subcutaneous tissue disorders | 125/508 |
| NASOPHARYNGITISInfections and infestations | 92/508 |
| UPPER RESPIRATORY TRACT INFECTIONInfections and infestations | 84/508 |
| HEADACHENervous system disorders | 80/508 |
| INFLUENZAInfections and infestations | 40/508 |
| URINARY TRACT INFECTIONInfections and infestations | 40/508 |
| ARTHRALGIAMusculoskeletal and connective tissue disorders | 38/508 |
| BRONCHITISInfections and infestations | 37/508 |
| DIARRHOEAGastrointestinal disorders | 33/508 |
| BACK PAINMusculoskeletal and connective tissue disorders | 33/508 |
Baseline characteristics provided by reporting groups defined by treatment received in the prior phase 3 studies, plus adalimumab every week (EW) received in M12-555. Baseline defined as the last measurement prior to the first dose of study drug in the prior phase 3 study (M11-810 or M11-310 for baseline characteristics.
| Age, Continuous(years) | EW/EW/EW | EW/EOW/EW | EW/PBO/EW | PBO/EW/EW | PBO/PBO/EW | Total |
|---|---|---|---|---|---|---|
| Mean | 35.5 ± 10.27 | 36.1 ± 10.50 | 36.5 ± 11.06 | 38.5 ± 11.92 | 37.0 ± 12.28 | 36.8 ± 11.35 |
| Sex: Female, Male(Participants) | EW/EW/EW | EW/EOW/EW | EW/PBO/EW | PBO/EW/EW | PBO/PBO/EW | Total |
|---|---|---|---|---|---|---|
| Female | 56 | 60 | 50 | 79 | 83 | 328 |
| Male | 32 | 30 | 42 | 36 | 40 | 180 |
No study locations are listed for this record.
Ran from Apr 2012 to primary completion in Aug 2016, 52 months.
Results were first posted in Sep 2017, 1 year 1 month after primary completion.
Of 26 phase 3 interventional studies under Hidradenitis Suppurativa, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 38. This study's 52 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Adalimumab
AbbVie (prior sponsor, Abbott) →